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Background: The impact of viral subtype on the rate of sustained virological response (SVR) to antiviral therapy in
patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated.
The aim of this study is to determine whether the HCV genotype 1 subtypes 1a and 1b respond differently to
treatment with PEGylated interferon (PEG-IFN) plus ribavirin.
Methods: For 48 weeks, 388 “naïve”genotype 1 patients were treated weekly with PEG-IFN α-2a or PEG-INF α-2b
combined with daily ribavirin (1000–1200 mg/day). The numbers of patients in whom HCV-RNA was undetectable
were compared after 4 (rapid virological response, RVR), 12 (early virological response, EVR), and 48 (end treatment
virological response, ETR) weeks of treatment as well as 24 weeks after the last treatment (sustained virological
response, SVR).
Results: The rate of SVR was higher in subtype 1a patients than subtype 1b patients (55% vs. 43%; p < 0.02).
Multiple logistic regression analysis showed that infection with genotype 1a (odds ratio(OR) : 1.8; 95% confidence
interval (CI): 1.4 to 4.1), age < 50 years (OR:7.0; 95% CI 1.1 to 21.2), alanine aminotransferase level (ALT)<100 IU/ml
(OR:2.1; 95% CI: 1.3 to3.5), HCV-RNA < 5.6 log10 IU/ml (OR: 3.2; 95% CI: 2.7 to 6.9) and fibrosis score < S3 (OR: 3.8;
95% CI:3.2 to 7.4), were all independent predictors of SVR.
Conclusion: Dual antiviral therapy is more effective against HCV subtype 1a than against subtype 1b and this
difference is independent of other factors that may favour viral clearance.
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Despite the promise of new antiviral drugs that can act
directly on hepatitis C viral replication such as protease
and polymerase inhibitors, a 48 weeks course of PEGy-
lated interferon (PEG-INF) combined with ribavirin
remains the current standard treatment for genotype 1
chronic hepatitis C (CHC) [1,2]. Extensive research has
shown that patients infected with HCV genotype 1
have a lower rate of viral response than those infected
with genotype 2 or 3. In large randomized multi-
national trials, PEGylated interferon α-2a plus ribavirin
has produced an SVR of about 50% in the more
difficult-to-treat subgroup of patients infected with
HCV genotype 1 [3,4]. Furthermore, advanced fibrosis
is a predictor of non response to antiviral treatment in
patients with genotype 1 virus [5-7]. Very few studies
have examined whether the subtype of genotype 1(1a
or 1b) affects the rate of SVR [7-10].
We have performed an observational study on a large
cohort of “naïve” HCV patients to evaluate the influence




A total of 11 regional centres affiliated with the CLEO
Group partecipate in the study between February 2007
and October 2010. Eligible subjects were naïve patients
infected with HCV genotype 1 virus who met the inter-
nationally recognised criteria for treatment (elevation of
aminotransferases and inflammation and/ or fibrosis at
liver biopsy). The exclusion criteria included co-infection
with human immunodeficiency virus (HIV) or hepatitis B
virus (HBV), alcohol intake averaging greater than 20 g
per day, active drug abuse, chronic systemic disease, psy-
chiatric disorders, autoimmune disease, pregnancy or lac-
tation. The following data were collected: age, gender,
body mass index (BMI) and Ishak score of liver biopsy
[11]. Of the 388 patients, 322 provided informed consent
for liver biopsy.
All patients received Peg-IFN α-2a at 180 μg/week or
PEG-INF α-2b at 1.5 μg/kg/week combined with riba-
virin at 1000 mg/day if the body weight was < 75 Kg or
1200 mg/day if the body weight was > 75 kg. The dose
of PEG-INF and ribavirin were modified as necessary
according to the standard criteria and protocol [12].
Patients with undetectable HCVRNA at week 4 were
considered rapid virological responders (RVR) and were
treated for full 48 weeks. Patients with a < 2 log decline
in HCVRNA at week 12 or who remained HCVRNA
positive at week 24 were considered to be non-responders
and did not continue with the treatment regimen. All
patients who withdrew from the study were also defined
as non-responders. The primary end point was sustainedundetectable serum HCVRNA 24 weeks after the end of
treatmen (SVR).HCVRNA quantification
Quantitative determination of HCVRNA (TaqMan Roche
Diagnostics). was performed before the treatment. The
TaqMan value used to determine the response was 15 IU/
ml. The TaqMan method is a standardised technique that
was used in all the CLEO group centres beginning in
December 2007. HCVRNA level was expressed as log10
IU/ml. HCVRNA was measured before the treatment, at
weeks 4,12,24,48 of treatment and 24 weeks after the final
treatment. HCV genotyping was performed using a hy-
bridisation technique (INNOLiPA HCV Immunogenetics).Statistical analysis
All analysis were performed on the basis of the intention
to treat (ITT);i.e., the denominator included all subjects
who received at least 1 dose of treatment.
Statistical analysis was performed using the Epiinfo
software package. All Data were expressed as the median
and range for discrete variables and as counts and per-
centages for qualitative variables. The differences be-
tween the groups were compared using non parametric
tests (the Mann Whitney U test for continuous variables
and χ2 test for parametric variables). A p value of < 0.05
was considered to be significant.
The crude odds ratios (O.R s) for the association of
SVR with different variables were evaluated by univariate
analysis. The following variables were analyzed: sex, age
(cut-off 50 years), ALT (cut-off 100 IU/ml), gamma-
glutamyltranspeptidase (GGT), BMI (cut-off 24.9), HCV-
RNA (cut-off 400,000 IU/ml), HCV genotype 1 subtype
( 1a or 1b), liver biopsy grade and stage score, and type
of PEGylated interferon received. The adjusted O.R.
were calculated by multiple logistic regression analysis
in order to identify independent predictors of SVR. Ad-
justment were made for all of the variables considered at
univariate analyses.Ethics
The study was approved by a central ethic committee
(San Camillo Hospital Rome Italy).Results
The study included 388 patients; of these 165 were
infected with HCV genotype 1 subtype 1a (42.5%)
and 223 with subtype 1b (57.5%). On average, subtype
1a patients were younger and had lower baseline HCV-
RNA levels than subtype 1b patients. All the baseline
characteristics of the 388 patients are reported
in Table 1.
Table 1 Baseline Characteristics of study population according to HCV subtype
Genotype 1a (n = 165) Genotype 1b (n = 223) P value
Sex (M/F) 120/45 123/100 0.001
Age (y) 45.0 ± 10.6 49.0 ± 12.1 0.0001
BMI (kg/m2) 24.1 ± 3.2 24.0 ± 3.3 ns
ALT (IU/ml) 109.2 ± 68.7 101.4 ± 61.2 ns
GGT (IU/ml) 65.1 ± 39.1) 67.3 ± 54.5 ns
Hgb (gr/dL) 15.2 ± 1.3 14.8 ± 1.9 ns
HCV-RNA ( log10 IU/ml) 5.72 ± 0.7 5.9 ± 0.5 0.006
HCV-RNA n (%)
≤ 5 .60 log10 52 (32) 44 (20) 0.01
> 5 .60 log10 113 (68) 179 (80) 0.01
Staging n (%)
≤ S3 111 (85) 151 (79) ns
> S3 19 (15) 41 (21) ns
Source of Infection n (%)
-BT 69 (41) 85 (38) ns
-DA 78 (47) 92 (41) ns
-S 8 (5) 15 (7) ns
-UN 11 (7) 32 (14) 0.03
Legend: M: male, F: female, y:years, BMI: body mass index, ALT: alanine aminotransferase value, GGT: gamma-glutamiltranspeptidasi, Hgb:Haemoglobin value, BT:
blood trasfusione, DA:drug abuse, S: sexual, UN: unknown.
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At week 4 of treatment HCV-RNA was undetectable
(RVR) in 77 genotype 1a patients (47%) and in 83 geno-
type 1b patients (37%) ( p < 0.07). At week 12 of treat-
ment 91 genotype 1a patients (55%) and 99 genotype 1b
patients (44%) had undetectable HCV-RNA (early viro-
logical response; EVR) (p < 0.04). At the end of treat-
ment 108 genotype 1a patients (65%) and 131 genotype
1b patients (58%) had undetectable HCV-RNA (p = n.s).
Seventeen (10%) of the genotype 1a patients and 32Figure 1 Rapid virological response (RVR), early virological response
virological response (SVR) and drop out in genotype 1 subtypes 1a a(14%) of the genotype 1b had detectable HCVRNA at
week 12 but not at week 24 (slow responders) (p = ns).
At the end of the treatment, there were 16 (9%) relapsed
patients in the genotype 1a group and 35(15%) in the
genotype 1b group (p = ns). Sustained virological re-
sponse was attained in 91 genotype 1a patients (55%)
and 96 genotype 1b patients (43%) ( p < 0.02). A total of
18 genotype 1a and 16 genotype 1b patients discontin-
ued all treatments at some time during the study owing
due adverse events (Figure 1).(EVR), end treatment virological response (ETR), sustained
nd 1b patients.
Table 2 Overall SVR according to different variables
Variable N° of pts/Tot pts SVR (%) P value
Sex
F 68/145 46 ns
M 119/243 49
Age
< 50 123/210 58 0.00001
> 50 64/178 37
BMI
< 25 145/280 51 0.05
> 25 32/82 39
ALT
< 100 139/261 53 0.002
> 100 51/127 40
HCV-RNA
≤ 5 .60 log10 64/96 66 0.00004
> 5 .60 log10 123/292 42
Genotype
1a 91/165 55 0.02
1b 96/223 43
Staging*
≤ S3 142/262 54 0.00008
> S3 15/60 25
Drug
PegINF α 2b 100/195 51 ns
PegINF α 2a 87/193 45
RVR
Yes 129/160 80 0.000001
No 58/228 25
Legend. SVR: sustained virological response, F: female, M:male, PegINF:
pegylated interferon, BMI: body mass index, ALT: alanine aminotransferase
value (IU/ml); RVR: rapid virological response.
*322 over 388 patients were submitted to liver biopsy and analyzed for this
variable.
Table 3 Factors associated with the likelihood of SVR.
Crude and adjusted Odds Ratios (O.R.) derived by
multiple logistic regression analysis
Crude O.R. (95% CI) Adjusted O.R. (C.I. 95%)
HCV-RNA≤ 5.6 log10
IU/ml
2.9 (1.8-5.1) 3.2 (2.7-6.9)
≤ S3* 3.8 (2.0-7.3) 3.8 (3.2-7.4)
Subtype 1a 1.9 (1.2-2.9) 1.8 (1.4-4.1)
Age 7.4 (0.9-40.0) 7.0 (1.1-21.2)
< 50
> 50
BMI 1.7 (1.0-2.8) 1.4 (0.8-2.5)
< 25
> 25
ALT 1.9 (1.2-3.0) 2.1 (1.3-3.5)
< 100
> 100
Sex 1.1 (0.7-1.7) 1.3 (0.8-2.2)
RVR 21.0 (11.5-38.3) 3.2 (1.3-7.7)
Legend O:R: odds ratio; BMI: body mass index, ALT: alanine aminotransferase
value IU/ml RVR rapid virological response.
*322over 388 patients were submitted to liver biopsy and analyzed for this
variable.
Table 4 Total discontinuation, dose modification and
adverse events related to antiviral treatment
Subtype 1a n = 165 Subtype 1b n = 223
Total discontinuation n (%) 18 (11) 16 (7.1)
-depression 7 (4.2) 3 (1.3)
-fatigue 10 (6) 9 (4)
-hyperthiroidism 0 1 (0.4)
-anemia 1 (0.6) 3 (1.3)
Adverse events n (%) 7 (4.2) 12 (5.3)
-depression 1 (0.6) 3 (1.3)
-hypothiroidism 1 (0.6) 0
-anemia 5 (3.0) 7 (3.1)
-neutropenia 0 2 (0.9)
Dose modification n (%) 16 (9.6) 24 (10.7)
Peginterferon 9 (5.4) 11 (5)
Ribavirin 7 (4.2) 13 (5.8)
n:number.
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The overall rate of SVR was 48.2%. Subtype 1a, age < 50
years, ALT value < 100 IU/ml, HCV-RNA< 400.000IU/ml
(< 5 .60 log10 IU/ml), and fibrosis score ≤ S3 were all fac-
tors predisposing to SVR (Table 2). The rate of SVR in
patients with fibrosis score S0-S3 was significantly higher
for subtype 1a (62%) than for subtype 1b (48%) ( p < 0.03);
while no statistically significant difference in SVR was
observed between the 2 subtypes (1a and 1b) in patients
scoring S4-S6 (31.5% vs. 28%; p = n.s.).(Data not shown).
Table 3 shows the crude and adjusted Odds Ratios
(ORs) for the associations of different variables with SVR.
After adjustment for the influence of the confounding
variables by logistic regression analysis, age < 50 (OR:7.0;
95% CI: 1.1 to 21.1), genotype 1a (OR: 1.8; 95% CI: 1.4 to
4.1), HCV-RNA < 5.6 log10 IU/ml (OR: 3.2; 95% CI: 2.7 to6.9), a fibrosis score ≤ S3 (OR: 3.8; 95% CI:3.2 to 7.4;), and
ALT value < 100 IU/ml (OR:2.1 95% CI: 1.3 to 3.5) were all
independent predictors of SVR while sex, and BMI were
not associated with SVR.
Cross-tabulation of RVR vs.SVR showed that the posi-
tive predictive value (PPV) of RVR for the achievement
of SVR was 82.0% for subtype 1a and 77.4% for subtype
1b (data not shown).
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Eighteen subtype 1a (11%) and 16 subtype 1b (7%)
patients stopped antiviral treatment due to adverse
effects. Six patients stopped during the first month of
treatment and the remaining patients during the follow-
ing months. The percentage of patients in both groups
whose treatment dose were decreased due to adverse
events were comparable: 9.6% (16 patients) for subtype
1a and 10.7% (24 patients) for subtype 1b. Anaemia was
the most frequent cause of dose reduction. Total discon-
tinuation, dose modifications and adverse events related
to treatment are showed in Table 4.
Discussion
We have conducted a large observational study to assess
the influence of viral subtype within HCV genotype 1 on
the virological response to antiviral treatment in naïve
HCV patients. Logistic regression analysis showed that
HCV subtype 1a, mild liver fibrosis scored as less than
S3 (Ishak score), HCV-RNA level less than 5.6 log10
IU/ml, age less than 50 years, and ALT level less than
100 IU/ml were all independent predictors of SVR.
Many efforts have been made to identify predictors of
SVR to antiviral treatment in the difficult-to- treat
chronic hepatitis C genotype 1 patients. Liver histology
and viral HCV-RNA levels seem to be particularly im-
portant predictor of response in these patients. A recent
study by Cheng et al. showed that naïve genotype-1
patients with advanced fibrosis were less likely to achieve
SVR than those without advanced fibrosis [5]. Bruno
et al. demonstrated that age and liver fibrosis predicted
the response rate to PEG-INF and ribavirin combination
therapy [6]. Few studies have investigated the impact of
viral subtype on SVR genotype 1 patients. A study by
Legrand-Abravanel et al. showed by multivariate analysis
that genotype 1 subtype 1a was associated with a lower
response to HCV therapy than subtype 1b [8]. However,
this was an observational study with some potential con-
funding factors: more than 23% of the patients were
concomitantly infected with HIV or HBV; and nearly
35% were interferon experienced patients. Similarly,
Nicot et al. found that genotype 1b and HCVRNA
< 15IU/ml were the only independent predictors of SVR
in genotype 1 patients. However the population of patients
analysed in this study was not homogeneous: 23% of all
patients were coinfected with HIV and 42% had not
responded to previous interferon treatment [9]. Zein et al.
found no difference in SVR rates between subtype 1a and
1b patients treated with standard interferon [13]. The
PROBE study, which included more than 6000 HCV
infected patients, showed that SVR was marginally asso-
ciated with subtype 1a ( OR 1.41; 95% CI 1.0-2.03) [7]. A
recent observational study with a retrospective and pro-
spective phase conducted in Italy (AIFA study), whichincluded naïve, relapser and no responder patients,
showed that genotype 1a naive patients experienced a rate
of SVR around 6% higher than that observed for genotype
1b naïve patients and comparable to that observed in
genotype 4 (retrospective phase-SVR G1a versus G1b 37.1
vs 31.6% p < 0.001 and prospective phase-SVR 31.0 vs
26.5% p < 0.001) [10]. A higher rate of adverse events and
in particular of anemia reported in AIFA study, could have
influenced the different rate of SVR observed respect to
our study. We hypothesize that, in particular, an high rate
of anemia could have been responsible for ribavirin or
peginterferon dose modification in the AIFA study (data
not reported).
Genotype 1 subtypes 1a and 1b are the most common
HCV genotypes in the United State. These subtypes are
also predominant in Europe and subtype 1b is respon-
sible for up to 73% of HCV infection in Japan. Zein et al.
found that patients with HCV subtype 1b were older on
average than those infected with other genotypes and
that subtype 1b may have been present in some coun-
tries before the other genotypes. All patients who
acquired HCV before 1955 were infected with subtype
1b. Subtype 1a was introduced in the late 1950s and
then, it became the most prevalent genotype [13].
According to this model HCV subtype 1b is associated
with more severe liver disease not because it is a more
aggressive form of HCV but because it reflect a longer
duration of infection [14]. In our study more genotype
1b than genotype 1a patients relapsed after treatment al-
though the difference was not statistically significance.
This difference could have been due to the higher per-
centage of slow responding patients in genotype 1b
group than in genotype 1a group. Some studies have
demonstrated a significant association between slow re-
sponse and relapse in patients with an EVR[15,16]. Al-
though genotype 1a present a lower age and lower
baseline HCVRNA level respect to genotype 1b patients,
the logistic regression analysis and in particular Adjusted
odds ratio shows the independent influence of genotype
1a on SVR without the disturbing influence of other
variables. For the above- mentioned reasons subtype 1b
patients may respond less favourably than subtype 1a
patients to PEG-INF plus ribavirin.
While we observed in dual antiviral therapy a better
SVR of genotype 1a respect to genotype 1b patients,
genotype 1a presents higher virologic failure respect to
genotype 1b in patients treated with triple antiviral com-
bination therapy including protease inhibitors Bocepre-
vir or Telaprevir. Overall, the barrier to resistance is
lower in genotype 1a than in genotype 1b strains, result-
ing in higher breakthrough rates in the former [17].
In our study we found similar SVR in patients treated
with pegylated interferon alfa-2a and alfa 2-b, this is in
agreement with Ideal and AIFA study [10,18] but it is in
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that demonstrated higher SVR in genotype 1 patients
treated with pegylated interferon alfa-2a [19,20]. At
present the superiority of one regimen over the other in
terms of treatment efficacy remains unknown. The per-
formance of the two drugs has not been explored in
patients stratified by treatment modifiers such as fibrosis
stage, basal viral load, insulin resistance, age and it is un-
likely that future effort will extend current knowledge as
we enter in the era of protease and polymerase inhibi-
tors [21].
The interleukin-28B (IL28B) polymorphism has been
reported to influence viral kinetics and SVR in genotype 1
patients [22]. We did not determine this parameter in the
present study; its significance was not known at the time
that the study was conducted. Therefore, we cannot ex-
clude the possibility that our subtype 1a patients may have
had a more favourable IL28B polymorphism profile than
did the subtype 1b patients. IL28B polymorphism could
be an additional parameter explaining the uniquely higher
SVR rate for subtype 1a versus 1b observed in the
Italian population.
Finally, we would like to emphasise that this study was
conducted in “real- world- patients”, thus providing a
representative picture of HCV treatment.
Conclusion
While in triple antiviral combination therapy including
protease inhibitors Boceprevir or Telaprevir genotype 1a
presents higher virologic failure respect to genotype 1b
patients, we observed in dual antiviral therapy a better
SVR of genotype 1a respect to genotype 1b patients that
is independent of other factors that may favour
viral clearance.
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